ECCO 2021

Novel agents: Do we need new drugs or just combinations?

Comparing the different modes of action in IBD: Selection & Positioning

IL23 inhibiton: Efficacy & Safety Updates

Role of JAKi in IBD: What’s new in 2021?

Therapeutic algorithms: How to define? Transfering trial data into routine care? Hit hard, hit early!

What are the therapeutic goals in IBD? Clinical goals vs. patient oriented goals (disease clearance, endoscopic healing, transmural healing, normal QoL, ...)

Artificial Intelligence in IBD ... Even today a part of clinical care!

Imaging: routine care vs. clinical trial setting? The predictive value of ultrasonography

Classification through AI is coming!

AI is coming!

AI - Has artificial intelligence reached IBD

AI: The new frontier in endoscopy interpretation

L'intelligence artificielle arrive dans la RCH !

AI está llegando!

Künstliche Intelligenz hilfreich bei Auswertung endoskopischer Befunde

Intelligenza artificiale: la nuova frontiera in endoscopia per la quantificazione dell'infiammazione intestinale

Need for early resection in Crohn's disease is not associated with poor prognosis - long-term follow-up data from Denmark

More JAK inhibitors - same questions!

SEAVUE: From efficacy to pharmacoeconomic perspectives

The SEAVUE Trial - will it help us to guide and position our treatment in Crohn's disease?

Which treatment for acute/severe UC after steroid failure

SEAVUE: no difference in remission between ustekinumab and adalimumab. Early treatment is most important!

SAEVUE: The 1st biologic head-to-head trial in Crohn's Disease

SEAVUE: Early intervention leads to great remission; STARDUST: Treat to Target - better for patients with high endoscopic disease

SEAVUE - Head-to-head comparison: Applicable for daily practice?

New Therapeutic Strategies: STARDUST treat-to-target trial with Ustekinumab in Crohn's Disease

Leczenie chirurgiczne na bardzo wczesnym etapie choroby Leśniowskiego-Crohna nie prognozuje niekorzystnego przebiegu choroby w obserwacji długoterminowej

Badanie SEAVUE - czy pomoże nam pozycjonować leki biologiczne i poprawić wyniki leczenia choroby Leśniowskiego-Crohna?

Enfin un seuil avec l'UCEIS !

SEAVUE: Early intervention leads to great remission; STARDUST: Treat to Target - better for patients with high endoscopic disease

Adalimumab vs Ustekinumab: dai risultati di confronto diretto alla partica clinica?

Welche Therapiestrategie für welches Therapieziel?

Liquid biopsy opens exciting window for biomarker monitoring

VARSITY: Epithelial neutrophils are very important actors in Ulcerative Colitis

Symsptoms and signs assocation - the value of histology

Liquid biopsy as a novel non-invasive biomarker in IBD

Towards UCEIS cutoff in UC

Hot topic: Intestinational ultrasound for disease monitoring in Crohn's Disease

PREdiCCt: Predictive factors associated with fatigue in IBD

Predictive value of Milan Ultrasound in UC

Quel traitement d'entretien en cas de colite aiguë grave cortico-sensible ?

Hot topic: Tarmultralyd til monitorering af Crohn's sygdom

PREdiCCt: Fatigue assoziierte prädiktive Faktoren

Prädiktiver Wert des Darmultraschalls bei UC

VIBRATO: Ritlecitinib and brepocitinib both effective. Ritlecitinib with more benefit from new mode of action.

ADVANCE and MOTIVATE: Risankizumab with fast induction kinetics

SELECTION updates: no apparent safety concerns for filgotinib

IL-23 inhibition with risankizumab effective for biologically treatment naive and preexposed patients (ADVANCE and MOTIVATE)

Upadacitinib significantly effective in UC (U-ACCOMPLISH)

Results form phase 3 induction studies with Upadacitinib in Ulcerative Colitis: U-ACCOMPLISH/U-ACHIEVE

Upadacitinib: Impressive induction data in Ulcerative Colitis

New drugs with signifiicant efficacy: ritlecitinib, brepocitinib, upadacitinib

IL-12/23 Blockade: Mechanism of action

New Therapeutic Treatments in IBD: JAKi

Anti-IL-23 Antikörper könnten potentielle Game-changer bei MC sein

Ritlecitinib und Brepocitinib: Neue Targets der JAK-Inhibition bei CU

Resultaten van de fase 3 inductie studies met upadacitinib in colitis ulcerosa: U-ACCOMPLISH/U-ACHIEVE

New drugs with signifiicant efficacy: ritlecitinib, brepocitinib, upadacitinib

Neue Aspekte zu IL-12 und IL-23-Antikörpern

Neue Daten zu JAK-Inhibitoren

Immune response to anti-SARS-CoV-2 vaccinations in different treatment subgroups of IBD patients. What has been clarified by the CLARITY IBD study so far?

5-ASA - back from the other side? New COVID-19 safety data from the SECURE-IBD cohort

Providing CLARITY on COVID-19 in IBD

Odpowiedź immunologiczna na szczepienia przeciw SARS-CoV-2 u chorych z IBD. Czy leczenie ma wpływ i co to może oznaczać dla naszych pacjentów?

5-ASA - powrót z zaświatów? Nowe dane z badania SECURE-IBD, dotyczące bezpieczeństwa terapii 5-ASA w dobie pandemii COVID-19.

Wide spectrum of treatments for IBD

Espectro de tratamientos amplio para IBD?

CRAFT UC: Diet more effective than FMT? We need more data

My perspective on ECCO2021

Fecal transplantation or diet for Ulcerative Colitis?

Appendectomy for Ulcerative Colitis

Increasing prevalence of IBD in Brazil

Update ECCO-Guideline on Vaccination and Vaccination Strategy

Konditionierte Diät ist der FMT bei CU überlegen

El ECCO 2021 desde mi punto de vista

Stoelgangstransplantatie of dieet voor colitis ulcera?

Appendektomi ved patienter med colitis ulcerosa

Stigende forekomst af IBD i Brasilien

Neue ECCO-Leitlinie zu Infektionen und Impstrategie